TheraVet SA (ALVET.PA)
EUR 0.11
(-0.46%)
EUR 0.11
(-0.46%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 12.78 Thousand EUR | 100.6% |
| 2022 | -2.13 Million EUR | 53.83% |
| 2021 | -4.62 Million EUR | -215.3% |
| 2020 | -1.46 Million EUR | -648.28% |
| 2019 | 267.81 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 740.35 Thousand EUR | 5690.82% |
| 2024 Q2 | 740.35 Thousand EUR | 0.0% |
| 2023 Q4 | 12.78 Thousand EUR | 0.01% |
| 2023 Q2 | 437.4 Thousand EUR | 0.0% |
| 2023 Q1 | 437.4 Thousand EUR | 120.46% |
| 2023 FY | 12.78 Thousand EUR | 100.6% |
| 2023 Q3 | 12.78 Thousand EUR | -97.08% |
| 2022 Q1 | -2.4 Million EUR | 48.01% |
| 2022 Q4 | -2.13 Million EUR | 0.0% |
| 2022 Q3 | -2.13 Million EUR | 11.2% |
| 2022 Q2 | -2.4 Million EUR | 0.0% |
| 2022 FY | -2.13 Million EUR | 53.83% |
| 2021 Q4 | -4.62 Million EUR | 0.0% |
| 2021 Q1 | -6.45 Million EUR | -339.34% |
| 2021 Q2 | -6.45 Million EUR | 0.0% |
| 2021 Q3 | -4.62 Million EUR | 28.23% |
| 2021 FY | -4.62 Million EUR | -215.3% |
| 2020 Q1 | 81.42 Thousand EUR | 0.0% |
| 2020 FY | -1.46 Million EUR | -648.28% |
| 2020 Q3 | -1.46 Million EUR | 14.41% |
| 2020 Q4 | -1.46 Million EUR | 0.0% |
| 2020 Q2 | -1.71 Million EUR | -2206.77% |
| 2019 FY | 267.81 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 101.791% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 100.007% |
| Adocia SA | 127 Thousand EUR | 89.933% |
| Aelis Farma SA | -16.19 Million EUR | 100.079% |
| Biophytis S.A. | 2.7 Million EUR | 99.527% |
| Advicenne S.A. | 12.17 Million EUR | 99.895% |
| genOway Société anonyme | 2.97 Million EUR | 99.57% |
| IntegraGen SA | -709.74 Thousand EUR | 101.801% |
| Medesis Pharma S.A. | 1.15 Million EUR | 98.896% |
| Neovacs S.A. | -237.08 Thousand EUR | 105.393% |
| NFL Biosciences SA | -2.27 Million EUR | 100.562% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 99.707% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 101.539% |
| Sensorion SA | 1.37 Million EUR | 99.072% |
| Theranexus Société Anonyme | 2.44 Million EUR | 99.477% |
| TME Pharma N.V. | -1.07 Million EUR | 101.185% |
| Valbiotis SA | -18.13 Million EUR | 100.07% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 99.414% |
| argenx SE | -1.83 Billion EUR | 100.001% |
| BioSenic S.A. | 28.04 Million EUR | 99.954% |
| Celyad Oncology SA | -6.1 Million EUR | 100.21% |
| DBV Technologies S.A. | -114.95 Million USD | 100.011% |
| Galapagos NV | -157.2 Million EUR | 100.008% |
| Genfit S.A. | -7.61 Million EUR | 100.168% |
| GeNeuro SA | 5.91 Million EUR | 99.784% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 100.051% |
| Innate Pharma S.A. | -30.71 Million EUR | 100.042% |
| Inventiva S.A. | 10.48 Million EUR | 99.878% |
| MaaT Pharma SA | -10.2 Million EUR | 100.125% |
| MedinCell S.A. | 39.5 Million EUR | 99.968% |
| Nanobiotix S.A. | -24.71 Million EUR | 100.052% |
| Onward Medical N.V. | -12.89 Million EUR | 100.099% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 99.106% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 99.953% |
| Oxurion NV | 10.71 Million EUR | 99.881% |
| Pharming Group N.V. | 99.4 Million EUR | 99.987% |
| Poxel S.A. | 44.55 Million EUR | 99.971% |
| GenSight Biologics S.A. | 16.29 Million EUR | 99.922% |
| Transgene SA | -14.4 Million EUR | 100.089% |
| Financière de Tubize SA | 78.62 Million EUR | 99.984% |
| UCB SA | 2.17 Billion EUR | 99.999% |
| Valneva SE | 82.73 Million EUR | 99.985% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 100.069% |